Skip to main content

Armodafinil Disease Interactions

There are 6 disease interactions with armodafinil.

Moderate

Armodafinil (applies to armodafinil) alcoholism

Moderate Potential Hazard, Moderate plausibility.

Patients with excessive sleepiness, including those taking armodafinil, should be frequently reassessed for their degree of sleepiness and, if appropriate, advised to avoid driving or any other potentially dangerous activity. Patients should refrain from drinking alcohol while taking armodafinil as any drug affecting the central nervous system (CNS) may alter judgment, thinking or motor skills.

References

  1. "Product Information. Nuvigil (armodafinil)." Cephalon Inc (2007):
Moderate

Armodafinil (applies to armodafinil) cardiovascular dysfunction

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Cardiovascular Disease, Valvular Heart Disease

Armodafinil may cause ECG changes, chest pain, or arrhythmia. Armodafinil should be used with caution in patients with cardiovascular complications. Armodafinil should not be used in patients with a history of left ventricular hypertrophy or in patients with mitral valve prolapse who have experienced the mitral valve prolapse syndrome when previously receiving CNS stimulants. It is recommended to monitor heart rate and blood pressure during treatment with armodafinil. Caution should be exercised when prescribing armodafinil to patients with known cardiovascular disease.

References

  1. "Product Information. Nuvigil (armodafinil)." Cephalon Inc (2007):
Moderate

Armodafinil (applies to armodafinil) liver dysfunction

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

In a study to determine the pharmacokinetics and metabolism of armodafinil in patients with cirrhosis, the oral clearance of armodafinil was decreased by about 60%, and the steady state concentration was doubled compared to healthy patients. The dosage of armodafinil should be reduced in patients with severe hepatic impairment. Close monitoring is recommended.

References

  1. "Product Information. Nuvigil (armodafinil)." Cephalon Inc (2007):
Moderate

Armodafinil (applies to armodafinil) psychiatric complications

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Psychosis, Depression

Armodafinil may cause adverse psychiatric reactions. Caution should be exercised when using this agent in patients with a history of psychosis, depression, or mania. If psychiatric symptoms develop in association with armodafinil administration, consider discontinuing armodafinil. Close monitoring of psychiatric symptoms is recommended.

References

  1. "Product Information. Nuvigil (armodafinil)." Cephalon Inc (2007):
Moderate

CNS stimulants (applies to armodafinil) bipolar disorders

Moderate Potential Hazard, Moderate plausibility.

Central nervous system (CNS) stimulants may induce a mixed/manic episode in patients with bipolar disorder. Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, and depression). Close monitoring is recommended when using these agents in patients with bipolar disorders.

References

  1. "Product Information. Fastin (phentermine)." SmithKline Beecham (2001):
  2. "Product Information. Cylert (pemoline)." Abbott Pharmaceutical (2001):
  3. "Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals (2001):
  4. "Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical (2001):
  5. "Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham (2001):
  6. "Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc (2001):
  7. "Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn (2001):
  8. "Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim (2001):
  9. "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals (2001):
  10. "Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals (2001):
  11. "Product Information. Focalin (dexmethylphenidate)." Mikart Inc (2001):
  12. "Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc (2007):
View all 12 references
Moderate

CNS stimulants (applies to armodafinil) psychotic disorders

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Psychosis

Central nervous system (CNS) stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder. Close monitoring is recommended when using these agents in patients with psychotic disorders.

References

  1. "Product Information. Fastin (phentermine)." SmithKline Beecham (2001):
  2. "Product Information. Cylert (pemoline)." Abbott Pharmaceutical (2001):
  3. "Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals (2001):
  4. "Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical (2001):
  5. "Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham (2001):
  6. "Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc (2001):
  7. "Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn (2001):
  8. "Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim (2001):
  9. "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals (2001):
  10. "Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals (2001):
  11. "Product Information. Focalin (dexmethylphenidate)." Mikart Inc (2001):
  12. "Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc (2007):
  13. "Product Information. Fintepla (fenfluramine)." Zogenix, Inc (2020):
View all 13 references

Armodafinil drug interactions

There are 439 drug interactions with armodafinil.

Armodafinil alcohol/food interactions

There is 1 alcohol/food interaction with armodafinil.


Report options

Share by QR Code
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.